Abstract
We determined the effects of etanercept on the serum concentrations of neuropeptides in RA patients. In a total of 11 patients who had been injected with etanercept, the serum levels of substance P, calcitonin gene-related peptide (CGRP), and gastrin-releasing peptide (GRP) were analyzed. Average levels of serum substance P were significantly reduced from 1.53 to 0.62 ng/ml after the injection of etanercept. In the CGRP and GRP analyses, these average levels dropped from 1.57 and 0.51 ng/ml to 0.44 and 0.04 ng/ml, respectively. Etanercept appears to decrease substance P levels with an improvement in disease activities.
MeSH terms
-
Adult
-
Aged
-
Antirheumatic Agents / therapeutic use*
-
Arthritis, Rheumatoid / drug therapy*
-
Arthritis, Rheumatoid / metabolism*
-
C-Reactive Protein / metabolism
-
Calcitonin Gene-Related Peptide / blood
-
Etanercept
-
Female
-
Gastrin-Releasing Peptide / blood
-
Humans
-
Immunoglobulin G / therapeutic use*
-
Male
-
Middle Aged
-
Receptors, Tumor Necrosis Factor / therapeutic use*
-
Substance P / blood*
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Substances
-
Antirheumatic Agents
-
Immunoglobulin G
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha
-
Substance P
-
Gastrin-Releasing Peptide
-
C-Reactive Protein
-
Calcitonin Gene-Related Peptide
-
Etanercept